Health, Medicine
The drug "Mildronate" (intramuscularly)
"Mildronate" injections contribute to inhibition of y-butyrobetaine hydroxylase, provoke a decrease in the level of free carnitine, reduce carnitine-dependent oxidation in fatty acids. The drug contributes to the improvement of metabolic processes, increases efficiency, reduces the manifestation of physical and mental overexertion. It also has a cardioprotective effect.
The drug "Mildronate" (intramuscularly) is prescribed with reduced working capacity, physical overstrain, in athletes including. The medication is recommended in the complex therapy of ischemic heart disease (with angina pectoris, chronic insufficiency, heart attack and dyshormonal cardiopathy), with abstinence syndrome against a background of chronic alcoholism (in combination with specific therapy). The medicine "Mildronate" (intramuscularly) is also used for disorders of (chronic and acute) cerebral blood supply, i.e. in the treatment of cerebral strokes and chronic insufficiency. In these cases, the drug is used as part of complex therapy.
The half-life of the drug is between three and six hours.
In chronic alcoholism, the drug "Mildronate" (intramuscularly) is recommended twice a day for half a gram, daily for seven or ten days.
If cerebral circulation is insufficient, in the acute phase of cerebrovascular pathology, five milliliters of a 10-percent solution is administered intravenously on a daily basis for ten days. Next, the medication is administered orally by half a gram daily. The duration of therapy is two or three weeks.
When the drug is used, dyspeptic phenomena, itching, psychomotor agitation, tachycardia, changes in arterial pressure are noted.
The safety of the drug during pregnancy has not been established. In this regard, the drug "Mildronate" (intramuscularly, intravenously and orally) is not assigned. If necessary, use the drug during lactation, feeding is recommended to be discontinued.
Similar articles
Trending Now